Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy

Targeting epigenetics using synthetic lethality in precision medicine

(2018) Ee Sin Chen   CELLULAR AND MOLECULAR LIFE SCIENCES

Advances in the systemic treatment of triple-negative breast cancer

(2018) J.M. Lebert et al.   Current Oncology

Therapeutic landscape in mutational triple negative breast cancer

(2018) Yaqin Shi et al.   Molecular Cancer

Metastatic and triple-negative breast cancer: challenges and treatment options

(2018) Sumayah Al-Mahmood et al.   Drug Delivery and Translational Research

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs

(2018) Anna Diana et al.   Current Oncology Reports

The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma

(2018) Sandra E. Ghayad et al.   CANCER BIOLOGY & THERAPY

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Molecular Processes Connecting DNA Methylation Patterns with DNA Methyltransferases and Histone Modifications in Mammalian Genomes

(2018) Albert Jeltsch et al.   Genes

Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer

(2016) Yuan Tang et al.   Clinical Breast Cancer

Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells

(2016) Raafat A. El-Awady et al.   DNA REPAIR

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Triple-negative breast cancer: is there a treatment on the horizon?

(2016) Hui Yao et al.   Oncotarget

HDAC Inhibitors as Novel Anti-Cancer Therapeutics

(2015) Cristabelle Souza et al.   Recent Patents on Anti-Cancer Drug Discovery

Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine

(2013) Olafur A. Stefansson et al.   AMERICAN JOURNAL OF PATHOLOGY

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

(2013) Berit Maria Müller et al.   BMC CANCER

Tamoxifen Resistance in Breast Cancer

(2012) Min-Sun Chang   Biomolecules & Therapeutics

Antagonism between curcumin and the topoisomerase II inhibitor etoposide

(2012) Ekram M. Saleh et al.   CANCER BIOLOGY & THERAPY

Epigenetics as a Therapeutic Target in Breast Cancer

(2012) Roisin Connolly et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy

(2011) Min-Yu Chen et al.   CANCER

Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells

(2011) Raafat A. El-Awady et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?

(2010) Raafat A. El-Awady et al.   ANTI-CANCER DRUGS

Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy

(2010) Michael Schnekenburger et al.   BIOCHEMICAL PHARMACOLOGY

Triple-negative breast cancer: Present challenges and new perspectives

(2010) Franca Podo et al.   Molecular Oncology

Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

(2009) Madhavi Billam et al.   BREAST CANCER RESEARCH AND TREATMENT

Epigenetics in cancer

(2009) S. Sharma et al.   CARCINOGENESIS

Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells

(2009) Ekram M. Saleh et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers

(2009) Yutaka Kondo   YONSEI MEDICAL JOURNAL

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance

(2008) Grazia Arpino et al.   ENDOCRINE REVIEWS

DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines

(2008) J Devon Roll et al.   Molecular Cancer